Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TWTR
Twitter, Inc.
TWTR
|
+$314M |
| 2 |
Dynatrace
DT
|
+$312M |
| 3 |
CoStar Group
CSGP
|
+$301M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$249M |
| 5 |
Clarivate
CLVT
|
+$237M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZNGA
ZYNGA INC. CL A COMMON
ZNGA
|
+$411M |
| 2 |
RTX Corp
RTX
|
+$335M |
| 3 |
CERN
Cerner Corp
CERN
|
+$312M |
| 4 |
Broadcom
AVGO
|
+$257M |
| 5 |
PLAN
Anaplan, Inc.
PLAN
|
+$102M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.97% |
| 2 | Technology | 17.59% |
| 3 | Financials | 14.68% |
| 4 | Industrials | 9.18% |
| 5 | Communication Services | 8.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
| $1.4B | 7.57% |
3,700,000
-2,011,000
| -35% | -$824M |
|
2
IQVIA
IQV
$42.8B
| $697M | 3.78% |
3,213,582
+96,000
| +3% | +$20.8M |
|
3
Thermo Fisher Scientific
TMO
$233B
| $675M | 3.66% |
1,242,459
+18,600
| +2% | +$10.2M |
|
4
TransUnion
TRU
$16.2B
| $597M | 3.24% |
7,462,996
+1,274,500
| +21% | +$110M |
|
5
Boston Scientific
BSX
$73B
| $561M | 3.04% |
15,047,257
-693,000
| -4% | -$28.2M |
|
6
Aramark
ARMK
$15.8B
| $490M | 2.66% |
22,171,104
-653,416
| -3% | -$16.1M |
|
7
Howmet Aerospace
HWM
$108B
| $435M | 2.36% |
13,837,353
+211,000
| +2% | +$7.23M |
|
8
Elevance Health
ELV
$86.9B
| $399M | 2.16% |
826,482
+57,707
| +8% | +$28.5M |
|
9
Centene
CNC
$32.1B
| $367M | 1.99% |
4,341,194
+288,850
| +7% | +$24M |
|
10
Mastercard
MA
$509B
| $363M | 1.97% |
1,151,271
+74,682
| +7% | +$25.7M |
|
11
Full Truck Alliance
YMM
$9.1B
| $359M | 1.95% |
39,675,743
+16,497,000
| +71% | +$112M |
|
|
12
Clarivate
CLVT
$1.33B
| $340M | 1.85% |
24,557,800
+15,844,372
| +182% | +$237M |
|
13
Wabtec
WAB
$50.3B
| $327M | 1.78% |
3,989,933
-917,997
| -19% | -$81.8M |
|
14
Microsoft
MSFT
$3.59T
| $327M | 1.77% |
1,272,878
-13,200
| -1% | -$3.58M |
|
15
Alphabet (Google) Class C
GOOG
$4.18T
| $314M | 1.7% |
2,868,140
-488,000
| -15% | -$57.7M |
|
|
16
Dynatrace
DT
$14.2B
| $309M | 1.68% |
+7,847,000
| New | +$312M |
|
17
AstraZeneca
AZN
$257B
| $306M | 1.66% |
2,314,981
+526,889
| +29% | +$69.1M |
|
|
ATVI
18
DELISTED
Activision Blizzard
ATVI
| $302M | 1.64% |
3,880,000
+530,000
| +16% | +$41.2M |
|
|
19
CoStar Group
CSGP
$13.1B
| $300M | 1.63% |
+4,963,185
| New | +$301M |
|
20
Equifax
EFX
$22.6B
| $296M | 1.6% |
1,617,357
+424,654
| +36% | +$85M |
|
|
SJR
21
DELISTED
Shaw Communications Inc.
SJR
| $292M | 1.58% |
9,917,000
-211,000
| -2% | -$6.11M |
|
22
Salesforce
CRM
$171B
| $290M | 1.57% |
1,758,938
+600
| +0% | +$106K |
|
23
Visa
V
$693B
| $288M | 1.56% |
1,462,810
+170,957
| +13% | +$35.3M |
|
24
Meta Platforms (Facebook)
META
$1.4T
| $287M | 1.56% |
1,781,040
-283,700
| -14% | -$54.7M |
|
|
BHVN
25
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $284M | 1.54% |
+1,947,820
| New | +$249M |
|
Similar funds
Thomas Steyer's Q2 2022 Portfolio in Review
As of Q2 2022, Thomas Steyer held 345 positions worth $18.4B, down 11% from $20.7B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Thomas Steyer withdrew a net $623M in Q2 2022, closing 30 positions and reducing 37 holdings. Its most notable exit was ZYNGA INC. CL A COMMON, an estimated $411M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Thomas Steyer opened a new position in Twitter, Inc. worth $274M.
- Thomas Steyer's largest Q2 2022 buy was Twitter, Inc.: 7,325,000 shares worth $274M.
- Thomas Steyer added most to Clarivate in Q2 2022, an estimated $237M increase.
- Thomas Steyer's biggest Q2 2022 reduction was AbbVie, cutting an estimated $97.7M.
- Thomas Steyer fully exited ZYNGA INC. CL A COMMON in Q2 2022, selling an estimated $411M.
- Thomas Steyer's ten largest holdings make up 32% of its $18.4B portfolio in Q2 2022.
- Thomas Steyer opened 22 new positions and closed 30 in Q2 2022.
- Thomas Steyer's portfolio value fell 11% quarter-over-quarter to $18.4B.
Based on Farallon Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.